ESMO 2026, INTerpath-014: Phase 3 study of adjuvant intismeran plus pembro SC or intismeran monotherapy vs placebo in HR stage I NSCLC

Moderna Inc. published this content on October 24, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 27, 2026 at 15:40 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]